Outcome Capital Congratulates ColonaryConcepts on Sale of Colon Preparation Business Unit to Sebela Pharmaceuticals
June 1, 2017, Boston, MA. Outcome Capital (outcomecapital.wpengine.com), a highly specialized investment banking firm that serves growth companies in the life sciences and technology sectors, is pleased to announce that its client, ColonaryConcepts, has completed the sale of its proprietary colonoscopy preparation assets to Sebela Pharmaceuticals, a pharmaceutical company specializing in gastrointestinal health. Sebela has secured worldwide rights to the unique colon prep technology, which integrates active ingredients into a patient-friendly kit consisting of USP-grade nutritionally balanced bars and beverages to improve the patient experience and compliance. Outcome Capital served as Exclusive Financial Advisor in this transaction. Financial terms were not disclosed.
Herbert Stern, co-founder and CEO of ColonaryConcepts commented: “We believe that our technology will also grow the market for colorectal screening by capturing a large subset of the patient population who forgo screening to avoid the highly unpleasant experience associated with currently marketed colon preparation products. We are delighted that our partners are in a position to integrate our technology into their extensive gastrointestinal channel.”
“Our approach has been enthusiastically supported by a large group of thought-leading gastroenterologists who will be excited to finally prescribe a highly differentiated purgative preparation,” said Dr. Corey Segal, co-founder of ColonaryConcepts. “We are thrilled to take this big step closer to bringing our novel bowel preparation to market. In practice, we hear daily how difficult the current preps are for patients, and we look forward to offering a significantly different experience.”
Dr. Oded Ben-Joseph, Managing Director of Outcome Capital, commented: “This transaction provides external validation for ColonaryConcepts’ innovative platform and will bring a much needed, paradigm-shifting approach for colonoscopy prep to the millions of patients annually who undergo colorectal cancer screening.”
Supported by a large body of intellectual property, ColonaryConcepts continues to expand its platform and pursue other follow-on products in therapeutic indications such as opioid-induced constipation where the development of its novel patient-friendly technology is relevant.
About Outcome Capital
Outcome Capital is a unique investment banking firm that provides middle-market growth companies in the life sciences, health care services and technology markets with a value-added client-centric approach to merger, acquisition and corporate finance advisory services. The firm utilizes its proven approach to value enhancement by assisting boards and management teams in navigating both the financial and strategic markets and in implementing the best path for success. Outcome Capital’s strength stems from its unique ability to draw on its wide range of operational, strategic and private equity experience, its expertise across the value chain, and its broad industry relationships. The professionals at Outcome Capital take pride in their ability to help their clients to make well-informed strategic decisions and recognize the full value created by their vision. For more information, visit: http://www.outcomecapital.com.
Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a leading provider of cancer registry solutions and compliance and informatics services, has been acquired by Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare technology and data analytics company with […]Read More
Outcome Capital Life Science Market Pulse October 2023 Click to view our LifeSciences Pulse NewsletterDownload